Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome.

[1]  P. McGuire,et al.  Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders , 2018, Schizophrenia bulletin.

[2]  R. Wang,et al.  Effect of the APP17 peptide on diabetic encephalopathy. , 2019, Journal of biological regulators and homeostatic agents.

[3]  A. Vincent,et al.  Antibody-mediated central nervous system diseases , 2018, Brain and neuroscience advances.

[4]  T. Theoharides,et al.  Stress, inflammation and natural treatments. , 2018, Journal of biological regulators and homeostatic agents.

[5]  G. Ricken,et al.  Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis , 2018, Front. Neurol..

[6]  T. Harrer,et al.  Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) , 2018, Journal of Translational Medicine.

[7]  A. Vincent,et al.  Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome , 2018, Neurology.

[8]  S. Kalra,et al.  Diabetes Fatigue Syndrome , 2018, Diabetes Therapy.

[9]  J. Dalmau,et al.  Antibody-Mediated Encephalitis. , 2018, The New England journal of medicine.

[10]  J. Blomberg,et al.  Infection Elicited Autoimmunity and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Explanatory Model , 2018, Front. Immunol..

[11]  M. Petruzzi,et al.  Depression and distress in burning mouth syndrome: A case control study. , 2018, Journal of biological regulators and homeostatic agents.

[12]  Mark M. Davis,et al.  Cytokine signature associated with disease severity in chronic fatigue syndrome patients , 2017, Proceedings of the National Academy of Sciences.

[13]  C. Jiang,et al.  Inflammation: The Common Pathway of Stress-Related Diseases , 2017, Front. Hum. Neurosci..

[14]  G. Plazzi,et al.  Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy , 2017, Sleep.

[15]  Ø. Fluge,et al.  Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. , 2016, JCI insight.

[16]  Y. Qian,et al.  Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption , 2016, Behavioural Brain Research.

[17]  D. Kullmann,et al.  Autoimmune synaptopathies , 2016, Nature Reviews Neuroscience.

[18]  M. Buckland,et al.  Chronic fatigue syndrome and circulating cytokines: A systematic review , 2015, Brain, Behavior, and Immunity.

[19]  Ø. Fluge,et al.  B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment , 2015, PloS one.

[20]  Hans Knoop,et al.  Chronic Fatigue in Type 1 Diabetes: Highly Prevalent but Not Explained by Hyperglycemia or Glucose Variability , 2013, Diabetes Care.

[21]  S. Hendrix,et al.  The role of mast cells in neuroinflammation , 2013, Acta Neuropathologica.

[22]  L. Facci,et al.  Microglia and mast cells: two tracks on the road to neuroinflammation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Ø. Fluge,et al.  Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study , 2011, PloS one.

[24]  Jin-Mann S. Lin,et al.  Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. , 2010, Metabolism: clinical and experimental.

[25]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[26]  D. Friedman,et al.  Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen , 2010, The Lancet Neurology.

[27]  M. Cuccia,et al.  Autoantibodies, Polymorphisms in the Serotonin Pathway, and Human Leukocyte Antigen Class II Alleles in Chronic Fatigue Syndrome , 2009, Annals of the New York Academy of Sciences.

[28]  A. Vincent,et al.  IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis† , 2008, Brain : a journal of neurology.

[29]  S. Kaech,et al.  Culturing hippocampal neurons , 2006, Nature Protocols.

[30]  A. Vincent,et al.  Detection and characterization of MuSK antibodies in seronegative myasthenia gravis , 2004, Annals of neurology.

[31]  T. Takano,et al.  Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. , 2003, International journal of molecular medicine.

[32]  D. Buchwald,et al.  High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome. , 1997, Arthritis and rheumatism.

[33]  K. Rowe.  Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. , 1997, Journal of psychiatric research.

[34]  D. Buchwald,et al.  Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. , 1996, The Journal of clinical investigation.

[35]  R. Klein,et al.  High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. , 1995, European journal of medical research.

[36]  I. Hickie,et al.  A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. , 1990, The American journal of medicine.